News and Comments

Dana-Farber Institute and Array Pharmaceutical Scientists to Work Together

  Tuesday, February 02, 2016

Yes. Dana-Farber Cancer Institute and Array Pharmaceuticals (ARRY) announced an immuno-oncology collaboration with potential applicability in a wide range of cancer indications.    More...


  Wednesday, July 31, 2013

Three biotechnology firms with market caps below $1billion have been recently put in the spotlight; SYNTA (SNTA) with a market cap of 535.54 million, ARRAY (ARRY) with a market cap of 774.22 million, and VANDA (VNDA) with a market cap of 320.45 million. More...

Array (ARRY): It is Difficult To have 14 Devils in Phase III trials

  Tuesday, August 16, 2011

One of the currently intriguing evaluations of a biotech firm is that of Array Pharmaceuticals (ARRY). Its stock has been incapable of luring investors regardless of how large is the number of its cancer products, how encouraging is the news about clinical trial results, or how generous are the upfront and promised milestone payments and royalties by the collaborating pharmaceutical companies. Array is a biotech firm that created an extraordinarily effective small molecule dug discovery and design technologies. Its technologies are state-of-the-art, built over advanced biochemistry and molecular biology. They include, high throughput screening, virtual screening, protein x-ray crystallography, structural databases and computational modeling – all assembled around a chemoinformatic databases and a library that has all sorts of molecules to pick from. The selection of molecules is made possible through its wide electronic laboratory notebook that enables scientists to generate novel predictive databases suitable for designing novel drugs out of existing molecules This drug discovery capability, which was seen by many as the most defining criterion in Array’s value, does not seem to included by the  evaluators of biotech firms. More...

Recent Postings



KERYX (KERX) Inovio (INO) SUNESIS PHARMACEUTICALS (SNSS) Micromet (MITI) SYNTA (SNTA) Intrexon (XON) Multiple Myeloma Velcade (bortezomib) Editas (EDIT) NOVOCURE (NVCR) Ionis (IONS) Regeneron (REGN) GlaxoSmithKline (GSK) galapagos (GLPG) Revlimid (lenolidamide) Benlysta (belimumab) Illumina (ILMN) Global Cell Therapeutics (GBT) Pluristem (PSTI) Sequenom (SQNM) Sanofi (SNA) ABBVIE (ABBV) Prosensa (RNA) ZALTRAP™ Sangamo (SGMO) Tysabri OSI (OSIP) GUARDIAN HEALTH NANTKWEST (NK) Ariad (ARIA) Epizyme (EPZM) Amgen (AMGN) Merck (MRK) AstraZeneca (AZN) INNOVIVA (INVA) Seattle Genetics (SGEN) Valeant Pharmaceuticals International (VRX) Mirati Therapeutics (MRTX) ISIS (ISIS) Human Genome Sciences (HGSI) Ridaforolimus Bristol-Myers Squibb (BMY) AERIE PHARMACEUTICALS SERES THERAPEUTICS (MCRB) CompuGen (CGEN) AGOS (ARGS) Aimmune Therapeutics (AIMT) LEXICON (LXRX) Adaptimmune (ADAP) Prolor Biotech (PBTH) Intercept (ICPT) Bellicum (BLCM) BIOMARIN (BMRN) OncoCyte (OCX) TOKAI (TKAOI) Advaxis (ADXS) VANDA (VNDA) Spike Therapeutics (ONCE) Sanofi (SNY) Exelixis (EXEL) Intermune (ITMN) Incyte (INCY) Akebia Therapeutics (AKAB) Agenus (AGEN Idenix (IDIX) Biogen Idec (BIIB) PTC Therapeutics (PTCT) C4 Therapeutics Ziofpharm (ZIOP) ADVENTRIX (ANX) Xoma (XOMA) Anacor (ANAC) Endometrial Cancer Dendreon (DNDN) Rapamune Trastuzumab-DM1 NEUROCRINE (NBIX) Dynavax (DVAX) Sanofi-Aventis (SAN) Auspex (ASPX) Theravance (THRX) Telaprevir ARGOS (ARGS) Sarepta (SRPT) Roche (RHHBY) Abbott Laboratories (ABT) HALOZYME (HALO) RenenxBio (RGNX) GlycoMimetics (GLYN) Cytokinetics (CYTK) KITE (KITE) CRISPR Therapeutics (CRSP) Vertex (VRTX) Agenus (AGEN) Herceptin Biocryst (BCRX) Gilead (GILD) Alder Biopharmaceuticals (ALDR) NEKTAR (NKTR)) CEMPRA (CEMP) JUNO (JUNO) JOUNCE THERAPEUTICS (JNCE) Ocular Therapeutix (OCUL) Theravance Bio Pharma (TBPH) Jazz Pharmaceuticals (JAZZ) Roche (ROCHE) ACADIA (ACAD) ARCA (ABIO) IDERA (IDRA) REGULUS (RGLS) Genentech MODERNA Human Longevity (HLI) Alnylam (ALNY) ImmunoGen (IMGN) Onyx (ONXX) Array Pharmaceuticals (ARRY) PORTOLA (PTLA) Zerenex Galena (GALE) Vitae Pharmaceuticals (VTAE) Anadys (ANDS) Elan (ELN)